Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | MCOLN2 | Q8IZK6 | 4/20 | 0.50 |
| ▸ | MCOLN1 | Q9GZU1 | 4/20 | 0.50 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698481 | 0.92 | SLC18A3 (0.61) | SLC18A3ALDH1A1DRD2DRD3MCOLN2 | |
| SCHEMBL13698567 | 0.92 | SLC18A3 (0.61) | SLC18A3ALDH1A1DRD2DRD3MCOLN2 | |
| SCHEMBL13698541 | 0.86 | ALDH1A1 (0.54) | SLC18A3ALDH1A1DRD2DRD3MCOLN3 | |
| SCHEMBL13698504 | 0.85 | ALDH1A1 (0.46) | SLC18A3ALDH1A1DRD2DRD3KDM4E | |
| SCHEMBL13698526 | 0.84 | KMT2A (0.46) | SLC18A3ALDH1A1DRD2DRD3MCOLN2 | |
| SCHEMBL13698535 | 0.84 | SLC18A3 (0.44) | SLC18A3ALDH1A1DRD2DRD3MCOLN2 | |
| SCHEMBL13698477 | 0.83 | HTR3E (0.52) | SLC18A3ALDH1A1DRD2 | |
| SCHEMBL13698486 | 0.83 | HTR3E (0.52) | SLC18A3ALDH1A1DRD2 | |
| SCHEMBL13698479 | 0.83 | HTR3E (0.52) | SLC18A3ALDH1A1DRD2 | |
| SCHEMBL13698566 | 0.83 | HTR3E (0.52) | SLC18A3ALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | BLANCO MIGUEL GARCIA-GUZMAN | 2009-09-24 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563795-B2 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239873-A1 | Phenyl-piperazine derivatives as modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | SLC18A3 187/4885ALDH1A1 2270/4885DRD2 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.